TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24309085

Group type: EXPERIMENTAL
Intervention: Grandparent Triple P intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (grandparent care-as-usual)
Number of subjects: 54
Study: 22472463

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Rehabilitation Program (PFRP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual health care (non-PFRP)
Number of subjects: 34
Study: 20688862

Group type: EXPERIMENTAL
Intervention: Volume targeted ventilation at 4 ml/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Volume targeted ventilation at 6 ml/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline (no volume targeting)
Number of subjects: 18
Study: 18466045

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15845715

Group type: EXPERIMENTAL
Intervention: Stimulating catheter technique
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional technique (blind advancement)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 81
Study: 14619648

Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 131
Study: 11056973

Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Follow-up examinations (neurological assessment including duplex sonography)
Number of subjects: 23
Study: 8985717

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CRH challenge
Number of subjects: 8
Study: 1420528

Group type: EXPERIMENTAL
Intervention: Braden Scale for Predicting Pressure Sore Risk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse judgment prediction method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention measures
Number of subjects: 0
Study: 6380331

Group type: EXPERIMENTAL
Intervention: Aerosol administration of 400 micrograms beclomethasone dipropionate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Powder administration of 400 micrograms beclomethasone dipropionate (Rotacaps)
Number of subjects: 40
Study: 31190751

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control with saline
Number of subjects: 120
Study: 28687982

Group type: EXPERIMENTAL
Intervention: ACB plus PCI (group B, ACB with 0.375% ropivacaine 30 ml + PCI with 0.2% ropivacaine 50 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ACB plus PCI (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACB (group A, ACB with 0.375% ropivacaine 30 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LIA (group C, local infiltration with 0.2% ropivacaine 100 ml)
Number of subjects: 60
Study: 27938853

Group type: EXPERIMENTAL
Intervention: DASH diet at low sodium
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: DASH diet at medium sodium
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: DASH diet at high sodium
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control diet (average American diet) at low sodium
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control diet (average American diet) at medium sodium
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control diet (average American diet) at high sodium
Number of subjects: 103
Study: 25295648

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 22897915

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI and bevacizumab for 3 months pre- and postoperative and resection (PERIMAX)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with FOLFOX and bevacizumab +/- irinotecan for a maximum of 6 months followed by maintenance treatment with fluoropyrimidine and bevacizumab (CHARTA)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Postoperative FOLFOX for 6 months (PERIMAX)
Number of subjects: 380

Group type: COMPARATOR
Intervention: FOLFOX and bevacizumab +/- irinotecan for a maximum of 6 months (CHARTA)
Number of subjects: 380
Study: 19383058

Group type: COMPARATOR
Intervention: Propranolol 80 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-dose metoprolol 190 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-dose metoprolol 95 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All beta-blocker treatments
Number of subjects: 11
Study: 17667485

Group type: EXPERIMENTAL
Intervention: Unmedicated/acutely ill PBD patients
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Medicated/clinically stabilized PBD patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: PBD subjects with comorbid ADHD
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: PBD subjects without ADHD
Number of subjects: 86
Study: 15592053

Group type: EXPERIMENTAL
Intervention: Slow shock wave lithotripsy (SWL) rate (60 pulses per minute)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Fast shock wave lithotripsy (SWL) rate (120 pulses per minute)
Number of subjects: 156
Study: 11849202

Group type: EXPERIMENTAL
Intervention: Test mucoadhesive solution (TS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference commercial solution (RS)
Number of subjects: 20
Study: 10634389

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Raloxifene - 60 mg/day
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Raloxifene - 120 mg/day
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 9193219

Group type: EXPERIMENTAL
Intervention: Topical budesonide powder (800 micrograms or 400 micrograms daily)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Surgical removal or a single injection of sustained released betamethasone (for failed therapy)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Not applicable (monitoring phase after treatment)
Number of subjects: 126
Study: 1487547

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3532680

Group type: EXPERIMENTAL
Intervention: Self-administered postoperative prophylactic positive expiratory pressure (S-PEP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (face-mask set without resistance)
Number of subjects: 75
Study: 30476246

Group type: COMPARATOR
Intervention: 8L:16D
Number of subjects: 480

Group type: COMPARATOR
Intervention: 14L:10D
Number of subjects: 480

Group type: COMPARATOR
Intervention: ≥12 h photoperiods
Number of subjects: 480
Study: 30060912

Group type: EXPERIMENTAL
Intervention: Standard consent plus visual aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgical consent
Number of subjects: 0
Study: 27908282

Group type: EXPERIMENTAL
Intervention: Case-management arm (multidimensional geriatric assessment and tailored interventions)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual-care arm (standard oncological care based on pre-defined oncological protocols)
Number of subjects: 1200
Study: 25399733

Group type: EXPERIMENTAL
Intervention: Low blood-pressure target (95/60 to 110/75 mm Hg)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Standard blood-pressure target (120/70 to 130/80 mm Hg)
Number of subjects: 558
Study: 23168367

Group type: EXPERIMENTAL
Intervention: R-CHOEP-14 (conventional chemotherapy with rituximab)
Number of subjects: 275

Group type: COMPARATOR
Intervention: R-MegaCHOEP (high-dose chemotherapy with rituximab)
Number of subjects: 275

Group type: COMPARATOR
Intervention: R-MegaCHOEP
Number of subjects: 275

Group type: COMPARATOR
Intervention: R-CHOEP-14
Number of subjects: 275
Study: 19762332

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 127
Study: 17850608

Group type: EXPERIMENTAL
Intervention: Topical 20% benzocaine gel
Number of subjects: 21

Group type: COMPARATOR
Intervention: Injected 2% lidocaine
Number of subjects: 21
Study: 16117898

Group type: EXPERIMENTAL
Intervention: BSE instruction group (132,979 women)
Number of subjects: 266064

Group type: COMPARATOR
Intervention: Control group (133,085 women)
Number of subjects: 266064
Study: 11817993

Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: methotrexate
Number of subjects: 482

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 482
Study: 10636366

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily for 50 days)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 7751733

Group type: EXPERIMENTAL
Intervention: 100 mg Lomefloxacin (LFLX)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 300 mg Lomefloxacin (LFLX)
Number of subjects: 119
Study: 2143361

Group type: EXPERIMENTAL
Intervention: Loratadine (Clarityn) 10 mg once daily
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Clemastine (Tavegyl) 1 mg twice daily
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 31844063

Group type: EXPERIMENTAL
Intervention: Corynebacterium + Dolosigranulum cluster at randomization (RD)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Moraxella cluster at yellow zone (YZ)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Corynebacterium relative abundance at YZ
Number of subjects: 319
Study: 28704156

Group type: EXPERIMENTAL
Intervention: TLC-NOSF matrix foam dressing (UrgoStart)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control dressing (neutral TLC foam dressing, UrgoTul Absorb)
Number of subjects: 187
Study: 26585638

Group type: EXPERIMENTAL
Intervention: SBIRT by non-physician providers and medical assistants (NPP and MA arm)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SBIRT by physicians (PCP arm)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (Control arm)
Number of subjects: 54
Study: 23924389

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU daily) in DMT2 patients
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Insulin + Oral agents
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 499

Group type: COMPARATOR
Intervention: Control group (Non-DMT2)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: All DMT2 groups
Number of subjects: 499
Study: 20585342

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 20134050

Group type: EXPERIMENTAL
Intervention: Oxygen breathing during mild resistive loading
Number of subjects: 8

Group type: COMPARATOR
Intervention: Air breathing during mild resistive loading
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxygen breathing during heavy resistive loading
Number of subjects: 8

Group type: COMPARATOR
Intervention: Air breathing during heavy resistive loading
Number of subjects: 8
Study: 17241415

Group type: EXPERIMENTAL
Intervention: Reloxin (Dysport, 20 U)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reloxin (Dysport, 50 U)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reloxin (Dysport, 75 U)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15500940

Group type: EXPERIMENTAL
Intervention: Fish gelatin (3.61 g cumulative dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish gelatin (7.61 g cumulative dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11571495

Group type: EXPERIMENTAL
Intervention: Single-limb endurance exercise training for 9 weeks
Number of subjects: 5
Study: 9610900

Group type: EXPERIMENTAL
Intervention: Filgrastim in MOPP arm
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Filgrastim in MOPP/EVAP arm
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no filgrastim) in MOPP arm
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no filgrastim) in MOPP/EVAP arm
Number of subjects: 47
Study: 7846367

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) followed by Endotracheal Tube (ETT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 20
Study: 3292699

Group type: EXPERIMENTAL
Intervention: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(7.9) EID50/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(7.25) EID50/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(5.7) EID50/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29269805

Group type: EXPERIMENTAL
Intervention: 5% DMSO
Number of subjects: 150

Group type: COMPARATOR
Intervention: 10% DMSO
Number of subjects: 150

Group type: COMPARATOR
Intervention: 7.5% DMSO
Number of subjects: 150
Study: 28403648

Group type: EXPERIMENTAL
Intervention: Apple-boysenberry beverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1/16 dilution of apple-boysenberry beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26091455

Group type: EXPERIMENTAL
Intervention: Task-oriented coping
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Emotion-oriented coping
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Avoidance-oriented coping
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Coping styles
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Burnout syndrome incidence
Number of subjects: 117
Study: 23327838

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 20348487

Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose-doxycycline (SDD)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 18429536

Group type: EXPERIMENTAL
Intervention: New device for urethral catheterization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comments from patients and nurses regarding the device
Number of subjects: 0
Study: 16557618

Group type: EXPERIMENTAL
Intervention: Clinician-identified risk cues
Number of subjects: 0
Study: 14578732

Group type: EXPERIMENTAL
Intervention: 500 mg of ursodeoxycholic acid daily for 6 months
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 10963247

Group type: EXPERIMENTAL
Intervention: HIV-1 voluntary counselling and testing (VCT)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: HIV-1 voluntary counselling and testing (VCT) targeting couples
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: HIV-1 voluntary counselling and testing (VCT) targeting high prevalence
Number of subjects: 10000
Study: 8970280

Group type: EXPERIMENTAL
Intervention: 20 gm supplement of All Bran and natural bran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1473667

Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg starting dose, titrated incrementally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (0.10 mg/kg starting dose, titrated incrementally)
Number of subjects: 0
Study: 6327927

Group type: EXPERIMENTAL
Intervention: Combined modality treatment with reinduction chemotherapy
Number of subjects: 453

Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone
Number of subjects: 453

Group type: COMPARATOR
Intervention: Three different chemotherapy regimens for remission induction
Number of subjects: 453

Group type: COMPARATOR
Intervention: Omission of chest irradiation
Number of subjects: 453

Group type: COMPARATOR
Intervention: Diagnosis by institutional pathologist
Number of subjects: 453
Study: 30315403

Group type: EXPERIMENTAL
Intervention: Home-based or group-based exercise (twice weekly for 1 year)
Number of subjects: 194
Study: 26966867

Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD) patients (both PD and HD)
Number of subjects: 27232

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 27232

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 27232

Group type: COMPARATOR
Intervention: Control group (without kidney disease)
Number of subjects: 27232
Study: 25487431

Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (UFP, O₃) during cycling
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (O₃) during cycling
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Personal exposure to PM(2.5)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Regional PM(2.5) concentrations
Number of subjects: 53
Study: 22495338

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation, physical activity, and socialization (active treatment group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 20214807

Group type: EXPERIMENTAL
Intervention: Physical coordination training or cognitive behavioral theory based training (CBTr) for cleaners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined physical exercise training, CBTr, and diet for health-care workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention for construction workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined physical exercise training, CBTr, and participatory ergonomics for industrial workers
Number of subjects: 0
Study: 17659768

Group type: EXPERIMENTAL
Intervention: Concrete nouns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All word classes and ambiguity conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Syntactically and semantically ambiguous items used as verbs
Number of subjects: 0
Study: 16379430

Group type: EXPERIMENTAL
Intervention: Sini decoction
Number of subjects: 65

Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 65
Study: 12939888

Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS) group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Non-CFS chronic fatigue group
Number of subjects: 141
Study: 10322592

Group type: EXPERIMENTAL
Intervention: Concentric isokinetic torque of plantar flexion (PF) at velocities of 30 degrees.s‐1, 60 degrees.s‐1, 120 degrees.s‐1, and 180 degrees.s‐1
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Angular delay at 180 degrees.s‐1
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Correlation of age with peak and mean torques
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Correlation of age with angular delay
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Correlation of age with maximal passive dorsiflexion (DF) angle and torque
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Correlation of age with peak torque velocity at 180 degrees.s‐1
Number of subjects: 81
Study: 9279998

Group type: EXPERIMENTAL
Intervention: Training of village health volunteers
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 1313
Study: 2001067

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study: 6390445

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of adriamycin
Number of subjects: 0
Study: 30416026

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 68
Study: 28240592

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 6092

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 6092

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID in LTE studies
Number of subjects: 6092

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID in LTE studies
Number of subjects: 6092
Study: 25029428

Group type: EXPERIMENTAL
Intervention: Tapering prednisolone for 6 months
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard therapy for 3 months followed by matching-placebo for 3 months
Number of subjects: 181
Study: 22716268

Group type: EXPERIMENTAL
Intervention: Multimedia (text and image) presentation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Text-only presentation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Image-only presentation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (unrelated information)
Number of subjects: 240
Study: 21483385

Group type: EXPERIMENTAL
Intervention: Epidural morphine (3 mg) before incision (MO1 group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural saline before incision and morphine after wound closure (MO2 group)
Number of subjects: 40
Study: 19760046

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Traditional oral feeding (TOF)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Nausea and vomiting, analgesic and antiemetic requirement, level of pain, quality of life
Number of subjects: 143
Study: 16816557

Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 14530809

Group type: EXPERIMENTAL
Intervention: TAC (docetaxel, doxorubicin, cyclophosphamide) 75/50/500 mg/m2 6xq3wk
Number of subjects: 61

Group type: COMPARATOR
Intervention: FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) 500/50/500 mg/m2 6x q3wk
Number of subjects: 61
Study: 11708695

Group type: EXPERIMENTAL
Intervention: Moist heat pack application for 20 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Static stretching for 30 seconds
Number of subjects: 30
Study: 9145856

Group type: EXPERIMENTAL
Intervention: Aminosidine sulfate (12 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aminosidine sulfate (15 mg/kg)
Number of subjects: 16